A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Auteurs

H. Bonnefoi, T. Grellety, O. Tredan, M. Saghatchian, F. Dalenc, A. Mailliez, T. L'Haridon, P. Cottu, S. Abadie-Lacourtoisie, B. You, M. Mousseau, J. Dauba, F. Del Piano, I. Desmoulins, F. Coussy, N. Madranges, J. Grenier, F.C. Bidard, C. Proudhon, G. MacGrogan, C. Orsini, M. Pulido, A. Gonçalves